1374582-32-7

Upstream product

• 81028-12-8 (4S,5R)-4-benzyloxymethyl-2,2-dimethyl-1,3-dioxolane-5-carboxaldehyde 
• 1374582-27-0 (5S,6S,Z)-7-benzyloxy-5,6-(isopropylidenedioxy)hept-3-en-2-one 
• 1445-45-0 Trimethyl orthoacetate 
• 1374582-31-6 (2S,3S,6R,Z)-1-benzyloxy-2,3-(isopropylidenedioxy)hept-4-en-6-ol 
• 1374582-30-5 (2S,3S,6S,Z)-1-benzyloxy-2,3-(isopropylidenedioxy)hept-4-en-6-ol 
• 1374582-29-2 (2S,3S,6R,E)-1-benzyloxy-2,3-(isopropylidenedioxy)hept-4-en-6-ol 
• 1374582-28-1 (2S,3S,6S,E)-1-benzyloxy-2,3-(isopropylidenedioxy)hept-4-en-6-ol 

Relevant academic research and scientific papers

Control of diastereoselectivity in orthoester Johnson-Claisen rearrangement of tartrate-based allyl alcohol: An efficient synthesis of arundic acid, a potential therapeutic agent for Alzheimer's disease

A diastereoselective orthoester Johnson-Claisen rearrangement has been employed in the synthesis of both enantiomers of arundic acid, a potential therapeutic agent against Alzheimer's disease. The effect of solvent, olefin geometry and alcohol chirality on the diastereoselectivity of the orthoester Johnson-Claisen rearrangement of a tartrate-based allyl alcohol has been studied. A diastereoselective orthoester Johnson-Claisen rearrangement has been employed in the synthesis of both enantiomers of arundic acid, a potential therapeutic agent for Alzheimer's disease. The effect of solvent, olefin geometry and alcohol chirality on the diastereoselectivity of the orthoester Johnson-Claisen rearrangement ofa tartrate-based allyl alcohol has beenstudied. Copyright